GLP-1 receptor agonists × glycemic control

SynthesisDiabetes research and clinical practice2023

Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.

Aihua Li et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 9,821 people · 2023

Randomised comparison

Lowered glycemic control

−1.06percentage points−1.30 to −0.81

As reported

difference −1.06 %, 95% CI −1.30 to −0.81

Randomised comparison

Lowered glycemic control

−0.26percentage points−0.38 to −0.15

As reported

difference −0.26 %, 95% CI −0.38 to −0.15

Two numbers in the abstract

the abstract, start to end

semaglutide 7 and 14 mg reduced HbA1c by 1.06% (95% CI, 0.81-1.30) and 1.10%

semaglutide 7 and 14 mg reduced HbA1c by 0.26% (95% CI, 0.15-0.38) and 0.38%

← favours treatmentfavours comparator →
could be chance
Glycemic control
−1.06−1.30 to −0.81
Glycemic control
−0.26−0.38 to −0.15
GLP-1 receptor agonistsOther glucose-loweringGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.91not counted

Other glucose-lowering × glycemic controlhelps?mixed

unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

22 papers cite it

2023
2024
2025
2026
this paperpooled itcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 36871874